The initial finding occurred in the laboratory of Leonard Zon, MD, chair of the HSCI Executive Committee and Professor of Stem Cell and Regenerative Biology at Harvard, who studies blood formation
in zebrafish at Boson Children's Hospital.; clinical research was conducted at Dana-Farber Cancer Institute and Massachusetts General Hospital, led by hematologic oncologist and HSCI Affiliated Faculty member Corey Cutler, MD, MPH; and Fate Therapeutics, Inc., a San Diego-based biopharmaceutical company of which Zon is a founder, sponsored the Investigational New Drug Application, under which the clinical program was conducted, and transplanted the research from the laboratory into the clinical setting.
Understanding the process of normal blood formation
in human adults is a crucial step in shedding light on what goes wrong during the process that results in leukemias, or cancers of the blood.
Czech scientists report they have proved that stem cells from dead donors can be transplanted to patients suffering from blood formation disorders such as leukemia, which is the first time in the world, according to Czech Science Academy press section.
The research team of Emanuel Necas and Ludek Sefc, which is from the Institute of Pathological Physiology of the 1st Medicine Faculty at Prague's Charles University, have discovered that stem cells from bone marrow, which are essential for blood formation, can be successfully transplanted even several hours after the donor's death.
They found that compounds that modulate blood flow had a potent impact on the expression of a master regulator of blood formation, known as Runx1.
The researchers showed that shear stress - the frictional force of fluid flow on the surface of cells lining the embryonic aorta - increases the expression of master regulators of blood formation, including Runx1, and of genetic markers found in blood stem cells.
This showed that biomechanical forces promote blood formation.